Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Receivables - Net: 2014-2021

Historic Receivables - Net for Agios Pharmaceuticals (AGIO) over the last 6 years, with Dec 2021 value amounting to $4.4 million.

  • Agios Pharmaceuticals' Receivables - Net was N/A to $4.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2021, which is N/A change from last year.
  • Per Agios Pharmaceuticals' latest filing, its Receivables - Net stood at $4.4 million for Q4 2021, which was up 87.57% from $2.3 million recorded in Q3 2020.
  • Agios Pharmaceuticals' 5-year Receivables - Net high stood at $19.3 million for Q2 2018, and its period low was $779,000 during Q2 2017.
  • Moreover, its 3-year median value for Receivables - Net was $2.4 million (2019), whereas its average is $2.5 million.
  • In the last 5 years, Agios Pharmaceuticals' Receivables - Net skyrocketed by 2,380.87% in 2018 and then crashed by 86.94% in 2019.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Receivables - Net stood at $2.4 million in 2017, then climbed by 0.57% to $2.5 million in 2018, then crashed by 37.49% to $1.5 million in 2019, then increased by 26.99% to $2.3 million in 2020, then reached $4.4 million in 2021.
  • Its Receivables - Net stands at $4.4 million for Q4 2021, versus $2.3 million for Q3 2020 and $2.5 million for Q2 2020.